EP2424507A4 - Compositions and methods for treating insulin resistance and diabetes mellitus - Google Patents

Compositions and methods for treating insulin resistance and diabetes mellitus

Info

Publication number
EP2424507A4
EP2424507A4 EP10770213A EP10770213A EP2424507A4 EP 2424507 A4 EP2424507 A4 EP 2424507A4 EP 10770213 A EP10770213 A EP 10770213A EP 10770213 A EP10770213 A EP 10770213A EP 2424507 A4 EP2424507 A4 EP 2424507A4
Authority
EP
European Patent Office
Prior art keywords
compositions
methods
diabetes mellitus
insulin resistance
treating insulin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP10770213A
Other languages
German (de)
French (fr)
Other versions
EP2424507A1 (en
Inventor
Richard L Watson
Anthony B Wood
Gregory J Archambeau
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Microdiffusion Inc
Original Assignee
Microdiffusion Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Microdiffusion Inc filed Critical Microdiffusion Inc
Publication of EP2424507A1 publication Critical patent/EP2424507A1/en
Publication of EP2424507A4 publication Critical patent/EP2424507A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0009—Galenical forms characterised by the drug release technique; Application systems commanded by energy involving or responsive to electricity, magnetism or acoustic waves; Galenical aspects of sonophoresis, iontophoresis, electroporation or electroosmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
EP10770213A 2009-04-27 2010-04-27 Compositions and methods for treating insulin resistance and diabetes mellitus Withdrawn EP2424507A4 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US17313409P 2009-04-27 2009-04-27
PCT/US2010/032620 WO2010126908A1 (en) 2009-04-27 2010-04-27 Compositions and methods for treating insulin resistance and diabetes mellitus

Publications (2)

Publication Number Publication Date
EP2424507A1 EP2424507A1 (en) 2012-03-07
EP2424507A4 true EP2424507A4 (en) 2012-10-24

Family

ID=43032520

Family Applications (1)

Application Number Title Priority Date Filing Date
EP10770213A Withdrawn EP2424507A4 (en) 2009-04-27 2010-04-27 Compositions and methods for treating insulin resistance and diabetes mellitus

Country Status (9)

Country Link
EP (1) EP2424507A4 (en)
JP (2) JP2012525396A (en)
CN (1) CN102413817B (en)
AU (1) AU2010241736B2 (en)
BR (1) BRPI1013992A2 (en)
CA (1) CA2758738A1 (en)
IL (1) IL215925A0 (en)
MX (1) MX2011011333A (en)
WO (1) WO2010126908A1 (en)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA030606B1 (en) 2006-05-04 2018-08-31 Бёрингер Ингельхайм Интернациональ Гмбх Methods of preparing a medicament comprising polymorphs
PE20080251A1 (en) 2006-05-04 2008-04-25 Boehringer Ingelheim Int USES OF DPP IV INHIBITORS
EP1852108A1 (en) 2006-05-04 2007-11-07 Boehringer Ingelheim Pharma GmbH & Co.KG DPP IV inhibitor formulations
US9523090B2 (en) 2007-10-25 2016-12-20 Revalesio Corporation Compositions and methods for treating inflammation
US9745567B2 (en) 2008-04-28 2017-08-29 Revalesio Corporation Compositions and methods for treating multiple sclerosis
US10125359B2 (en) 2007-10-25 2018-11-13 Revalesio Corporation Compositions and methods for treating inflammation
PE20140960A1 (en) 2008-04-03 2014-08-15 Boehringer Ingelheim Int FORMULATIONS INVOLVING A DPP4 INHIBITOR
US20200155558A1 (en) 2018-11-20 2020-05-21 Boehringer Ingelheim International Gmbh Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug
US8623395B2 (en) 2010-01-29 2014-01-07 Forsight Vision4, Inc. Implantable therapeutic device
CA3045436A1 (en) 2009-01-29 2010-08-05 Forsight Vision4, Inc. Posterior segment drug delivery
WO2013022801A1 (en) 2011-08-05 2013-02-14 Forsight Vision4, Inc. Small molecule delivery with implantable therapeutic device
JP5907966B2 (en) 2010-08-05 2016-04-26 フォーサイト・ビジョン フォー・インコーポレーテッド Implantable therapy device
WO2012019139A1 (en) 2010-08-05 2012-02-09 Forsight Vision4, Inc. Combined drug delivery methods and apparatus
US9033911B2 (en) 2010-08-05 2015-05-19 Forsight Vision4, Inc. Injector apparatus and method for drug delivery
AU2011289172B2 (en) 2010-08-12 2015-09-24 Revalesio Corporation Compositions and methods for treatment of taupathy
KR102117282B1 (en) * 2010-11-15 2020-06-01 베링거 인겔하임 인터내셔날 게엠베하 Vasoprotective and cardioprotective antidiabetic therapy
US9034883B2 (en) * 2010-11-15 2015-05-19 Boehringer Ingelheim International Gmbh Vasoprotective and cardioprotective antidiabetic therapy
EP2640360A2 (en) 2010-11-19 2013-09-25 Forsight Vision4, Inc. Therapeutic agent formulations for implanted devices
US20120263764A1 (en) * 2011-04-13 2012-10-18 Revalesio Corporation Compositions and methods for inhibiting and/or modulating effector t-cells involved in inflammatory neurodegenerative disease
WO2013003620A2 (en) 2011-06-28 2013-01-03 Forsight Vision4, Inc. Diagnostic methods and apparatus
EP3903733A1 (en) 2011-09-16 2021-11-03 ForSight Vision4, Inc. Fluid exchange apparatus
WO2013116061A1 (en) 2012-02-03 2013-08-08 Forsight Vision4, Inc. Insertion and removal methods and apparatus for therapeutic devices
JP6159584B2 (en) * 2012-06-14 2017-07-05 松本　高明 Infusion, infusion production method and infusion device
CH706747A2 (en) * 2012-07-17 2014-01-31 Hanspeter Steffen Process for hydration, tightening and care of the skin, for the treatment of dermatoses, sunburn and general wounds with electrolysis water produced with diamond electrodes.
GB201300684D0 (en) 2013-01-15 2013-02-27 Apitope Int Nv Peptide
EP2968113B8 (en) 2013-03-14 2020-10-28 Forsight Vision4, Inc. Systems for sustained intraocular delivery of low solubility compounds from a port delivery system implant
CA2907681C (en) 2013-03-28 2022-11-22 Forsight Vision4, Inc. Ophthalmic implant for delivering therapeutic substances
US20170056438A1 (en) * 2014-10-17 2017-03-02 Aqua Zest Corporation Nanobubble-containing composition and use thereof
WO2015099201A1 (en) * 2013-12-27 2015-07-02 アクア・ゼスト株式会社 Nanobubble-containing composition and use thereof
RU2695563C2 (en) 2014-07-15 2019-07-24 Форсайт Вижн4, Инк. Method and device for eye implant delivery
US9474756B2 (en) 2014-08-08 2016-10-25 Forsight Vision4, Inc. Stable and soluble formulations of receptor tyrosine kinase inhibitors, and methods of preparation thereof
CN114587774A (en) 2014-11-10 2022-06-07 弗赛特影像4股份有限公司 System for treating an eye
JP6674748B2 (en) * 2015-05-27 2020-04-01 花王株式会社 GLP-1 secretagogue
KR20180084104A (en) 2015-11-20 2018-07-24 포사이트 비젼4, 인크. Porous structures for extended release drug delivery devices
AR108177A1 (en) 2016-04-05 2018-07-25 Forsight Vision4 Inc DEVICES FOR SUPPLY OF IMPLANTABLE OCULAR DRUGS
CN105878194A (en) * 2016-06-07 2016-08-24 沈阳药科大学 Glibenclamide nanocrystal preparation and preparation method thereof
CN106362166B (en) * 2016-10-27 2019-12-10 武汉大学 Function and application of tumor necrosis factor receptor-related pan-scaffold and signaling protein in treatment of fatty liver and type II diabetes
BR112020010053A2 (en) 2017-11-21 2020-11-03 Forsight Vision4, Inc. fluid change device for expandable door release system and methods of using it
CN110006871A (en) * 2019-02-20 2019-07-12 常州大学 One cell model and application based on exogenous histamine detection

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992005792A1 (en) * 1990-10-02 1992-04-16 Buchholz Klaus L Use of the reaction product of a gas and a liquid, as well as process and device for producing the same
WO2002060458A2 (en) * 2001-02-01 2002-08-08 Hydron Technologies, Inc. Compositions and method of tissue superoxygenation
WO2006133113A2 (en) * 2005-06-03 2006-12-14 BAGLEY David System for making and conditioning super-oxygenated and structured water
WO2008052143A2 (en) * 2006-10-25 2008-05-02 Revalesio Corporation Mixing device and output fluids of same
WO2009055614A1 (en) * 2007-10-25 2009-04-30 Revalesio Corporation Compositions and methods for modulating cellular membrane-mediated intracellular signal transduction
WO2009055729A1 (en) * 2007-10-25 2009-04-30 Revalesio Corporation Compositions and methods for treating inflammation

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7196164B2 (en) * 1997-07-08 2007-03-27 Human Genome Sciences, Inc. Secreted protein HHTLF25
US6861227B2 (en) * 1998-03-19 2005-03-01 Human Genome Sciences, Inc. Antibodies to cytokine receptor common gamma chain like
US6902902B2 (en) * 2001-11-27 2005-06-07 Arena Pharmaceuticals, Inc. Human G protein-coupled receptors and modulators thereof for the treatment of metabolic-related disorders
AU2007308840C1 (en) * 2006-10-25 2014-09-25 Revalesio Corporation Methods of therapeutic treatment of eyes and other human tissues using an oxygen-enriched solution
US20080154795A1 (en) * 2006-12-25 2008-06-26 Amos Alon Auction platform and applications
JP2008156320A (en) * 2006-12-26 2008-07-10 Hydrox Kk Antioxidative functional water

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992005792A1 (en) * 1990-10-02 1992-04-16 Buchholz Klaus L Use of the reaction product of a gas and a liquid, as well as process and device for producing the same
WO2002060458A2 (en) * 2001-02-01 2002-08-08 Hydron Technologies, Inc. Compositions and method of tissue superoxygenation
WO2006133113A2 (en) * 2005-06-03 2006-12-14 BAGLEY David System for making and conditioning super-oxygenated and structured water
WO2008052143A2 (en) * 2006-10-25 2008-05-02 Revalesio Corporation Mixing device and output fluids of same
WO2009055614A1 (en) * 2007-10-25 2009-04-30 Revalesio Corporation Compositions and methods for modulating cellular membrane-mediated intracellular signal transduction
WO2009055729A1 (en) * 2007-10-25 2009-04-30 Revalesio Corporation Compositions and methods for treating inflammation

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of WO2010126908A1 *

Also Published As

Publication number Publication date
AU2010241736B2 (en) 2016-01-28
EP2424507A1 (en) 2012-03-07
IL215925A0 (en) 2011-12-29
AU2010241736A1 (en) 2011-12-22
BRPI1013992A2 (en) 2016-08-16
CA2758738A1 (en) 2010-11-04
CN102413817A (en) 2012-04-11
MX2011011333A (en) 2011-11-18
CN102413817B (en) 2014-12-17
JP2012525396A (en) 2012-10-22
JP2015229678A (en) 2015-12-21
WO2010126908A1 (en) 2010-11-04

Similar Documents

Publication Publication Date Title
EP2424507A4 (en) Compositions and methods for treating insulin resistance and diabetes mellitus
HK1224144A1 (en) Methods and compositions for weight management and for improving glycemic control
IL205554A (en) Composition for treating insulin resistance comprising melanocortins
ZA201200224B (en) Long acting insulin composition
PL2252312T3 (en) Methods for preventing or treating insulin resistance
PL3181134T3 (en) Bifidobacteria for treating diabetes and related conditions
EP2120959A4 (en) Methods and compositions for the treatment of insulin resistance, diabetes, and diabetes-associated dyslipidemia
HK1161275A1 (en) Halogen-stabilized insulin
EP2414535A4 (en) Biomarkers related to insulin resistance and methods using the same
ZA201100056B (en) Syringe with disabling mechanism
HK1164112A1 (en) Treating hyperglycemia with glp-1 glp-1
ZA201005628B (en) Injection syringe
LT2376077T (en) Composition and method for treatment of diabetes
EP2067781A4 (en) Agent for improving insulin resistance
EP2386624A4 (en) Complex microbial preparation for treating diabetes and preparative method and use thereof
EP2480246A4 (en) Composition and method for treatment of diabetes
HK1145452A1 (en) A pharmaceutical composition for treating diabetic nephropathy and the preparation method thereof
GB201009713D0 (en) A pharmaceutical composition for treating diabetes and preparation methods thereof
EP2797619A4 (en) Glypican-4 based compositions and methods for treating and diagnosing insulin resistance
PT2557920E (en) Composition comprising powdered eggshell membrane for use in treating diabetes mellitus
PT2459207E (en) Pharmaceutical composition for use in treating obesity, diabetes or to increase insulin sensitivity
HK1157690A1 (en) Syringe
EP2035031A4 (en) Insulin composition
GB0812019D0 (en) Insulin
EP2455090A4 (en) Agent for inhibiting increase in postprandial blood insulin level

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20111124

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO SE SI SK SM TR

DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20120926

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 47/02 20060101ALI20120920BHEP

Ipc: A61K 9/08 20060101ALI20120920BHEP

Ipc: A61K 31/58 20060101ALI20120920BHEP

Ipc: A61K 33/00 20060101ALI20120920BHEP

Ipc: A61K 9/00 20060101ALI20120920BHEP

Ipc: A61K 45/06 20060101ALI20120920BHEP

Ipc: A61K 9/14 20060101AFI20120920BHEP

17Q First examination report despatched

Effective date: 20151008

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20171103